Crossject reports audited financial results for 2023

Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency...

Related Keywords

Natasha Drapeau ,Sophie Baumont ,Us Biomedical Advanced Research ,Development Authority ,Euronext ,Research Tax Credit ,Cohesion Bureau ,France April ,Advanced Research ,Paris Stock Exchange Alcj ,Crossject ,